Vaccination against infection in patients with multiple sclerosis

Nature Reviews Neurology

Volumn 8, Issue 3, 2012, Pages 143-151

  Loebermann, Micha ^a   Winkelmann, Alexander ^a   Hartung, Hans Peter ^b   Hengel, Hartmut ^b   Reisinger, Emil C ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYTOSTATIC AGENT; DIPHTHERIA VACCINE; FINGOLIMOD; GLUCOCORTICOID; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PLACEBO; POLIOMYELITIS VACCINE; RABIES VACCINE; RITUXIMAB; ROTAVIRUS VACCINE; TETANUS TOXOID; TICK BORNE ENCEPHALITIS VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; CHICKENPOX; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DIPHTHERIA; DRUG EFFICACY; DRUG INDICATION; DRUG INHIBITION; DRUG SAFETY; HEPATITIS B; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; INFLUENZA; MEASLES; MONOTHERAPY; MULTIPLE SCLEROSIS; MUMPS; PAPILLOMAVIRUS INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; ROTAVIRUS INFECTION; RUBELLA; SYSTEMIC LUPUS ERYTHEMATOSUS; TETANUS; TETANUS PROPHYLAXIS; TICK BORNE ENCEPHALITIS; YELLOW FEVER;

BACTERIAL INFECTIONS; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; VACCINATION; VIRUS DISEASES;

EID: 84858159489     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.8     Document Type: Review

References (90)

1. Ascherio, A. & Munger, K. L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61, 288-299 (2007).
2. Handel, A. E., Giovannoni, G., Ebers, G. C. & Ramagopalan, S. V. Environmental factors and their timing in adult-onset multiple sclerosis. Nat. Rev. Neurol. 6, 156-166 (2010).
3. Correale, J., Fiol, M. & Gilmore, W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 67, 652-659 (2006).
4. Buljevac, D. et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125, 952-960 (2002).
5. Salemi, S. & D'Amelio, R. Could autoimmunity be induced by vaccination? Int. Rev. Immunol. 29, 247-269 (2010).
6. Stratton, K. F. et al. (Eds) Adverse Effects of Vaccines: Evidence and Causality (The National Academies Press, Washington, DC, 2011).
7. Farez, M. F. & Correale, J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J. Neurol. 258, 1197-1206 (2011).
8. Global Advisory Committee on Vaccine Safety. Causality assessment of adverse events following immunization. Wkly Epidemiol. Rec. 76, 85-89 (2001).
9. Jelinek, G. A. & Hassed, C. S. Managing multiple sclerosis in primary care: are we forgetting something? Qual. Prim. Care 17, 55-61 (2009).
10. Meyer-Olson, D. & Witte, T. Prevention of infections in patients with autoimmune diseases. Nat. Rev. Rheumatol. 7, 198-200 (2011).
11. National Collaborating Centre for Chronic Conditions (UK). Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. National Institute for Health and Clinical Excellence [online], http://www.nice.org.uk/nicemedia/pdf/cg008guidance.pdf (2003).
12. Rutschmann, O. T., McCrory, D. C. & Matchar, D. B. Immunization and MS: a summary of published evidence and recommendations. Neurology 59, 1837-1843 (2002).
13. STIKO. Recommendation of the Standing Vaccination Commission. Epidemiol. Bull. 30, 279-298 (2010).
14. Zipp, F. & Wandinger, K. P. Current recommendations for vaccination in multiple sclerosis. Nervenarzt 73, 384 (2002).
15. DeStefano, F. et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch. Neurol. 60, 504-509 (2003).
16. Confavreux, C. et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N. Engl. J. Med. 344, 319-326 (2001).
17. De Keyser, J. Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection 26, 319 (1998).
18. Hernan, M. A., Alonso, A. & Hernandez-Diaz, S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 67, 212-215 (2006).
19. De Keyser, J., Zwanikken, C. & Boon, M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J. Neurol. Sci. 159, 51-53 (1998).
20. Moriabadi, N. F. et al. Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 56, 938-943 (2001).
21. Salvetti, M. et al. Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J. Neurol. 242, 143-146 (1995).
22. Michielsens, B., Wilms, G., Marchal, G. & Carton, H. Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. Eur. Neurol. 30, 258-259 (1990).
23. Sibley, W. A., Bamford, C. R. & Laguna, J. F. Influenza vaccination in patients with multiple sclerosis. JAMA 236, 1965-1966 (1976).
24. Miller, A. E. et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48, 312-314 (1997).
25. Farez, M. F., Ysrraelit, M. C., Fiol, M. & Correale, J. H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study. Mult. Scler. http://dx.doi.org/10.1177/ 1352458511417253.
26. Auriel, E., Gadoth, A., Regev, K. & Karni, A. Seasonal and H1N1v influenza vaccines in MS: safety and compliance. J. Neurol. Sci. http://dx.doi.org/10.1016/j.jns.2011.10.013.
27. Bardage, C. et al. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 343, d5956 (2011).
28. Lee, G. M. et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am. J. Prev. Med. 41, 121-128 (2011).
29. Williams, S. E. et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine 29, 8302-8308 (2011).
30. McNicholas, N. & Chataway, J. Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J. Neurol. 258, 1545-1547 (2011).
31. Mansfield, K. L. et al. Tick-borne encephalitis virus - a review of an emerging zoonosis. J. Gen. Virol. 90, 1781-1794 (2009).
32. Gao, X., Nasci, R. & Liang, G. The neglected arboviral infections in mainland China. PLoS Negl. Trop. Dis. 4, e624 (2010).
33. Baumhackl, U., Franta, C., Retzl, J., Salomonowitz, E. & Eder, G. A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine 21 (Suppl. 1), S56-S61 (2003).
34. Veit, O. et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin. Infect. Dis. 48, 659-666 (2009).
35. Farez, M. F. & Correale, J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch. Neurol. 68, 1267-1271 (2011).
36. Hocine, M. N. et al. Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. Vaccine 25, 5938-5943 (2007).
37. Jefferson, T. & Heijbel, H. Demyelinating disease and hepatitis B vaccination: is there a link? Drug Saf. 24, 249-254 (2001).
38. Mikaeloff, Y., Caridade, G., Rossier, M., Suissa, S. & Tardieu, M. Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch. Pediatr. Adolesc. Med. 161, 1176-1182 (2007).
39. Ascherio, A. et al. Hepatitis B vaccination and the risk of multiple sclerosis. N. Engl. J. Med. 344, 327-332 (2001).
40. Terney, D. et al. Multiple sclerosis after hepatitis B vaccination in a 16-year-old patient. Chin. Med. J. (Engl.) 119, 77-79 (2006).
41. Cabrera--Gomez, J. A. et al. A severe episode in a patient with recurrent disseminated acute encephalitis due to vaccination against hepatitis B. For or against vaccination? Rev. Neurol. 34, 358-363 (2002).
42. Mikaeloff, Y. et al. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain 130, 1105-1110 (2007).
43. Sutton, I., Lahoria, R., Tan, I., Clouston, P. & Barnett, M. CNS demyelination and quadrivalent HPV vaccination. Mult. Scler. 15, 116-119 (2009).
44. Menge, T. et al. Neuromyelitis optica following human papillomavirus vaccination. Neurology (in press).
45. Centers for Disease Control and Prevention (CDC). Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb. Mortal. Wkly Rep. 45, 603-606 (1996).
46. Sibley, W. A. & Foley, J. M. Infection and immunization in multiple sclerosis. Ann. NY Acad. Sci. 122, 457-466 (1965).
47. Anderson, E. J. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect. Dis. 8, 642-649 (2008).
48. Plotkin, S. A. & Wiktor, T. Rabies vaccination. Annu. Rev. Med. 29, 583-591 (1978).
49. Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H. P. & Zettl, U. K. Fingolimod treatment for multiple sclerosis. What do we do with varicella? Ann. Neurol. 70, 673-674 (2011).
50. European Medicines Agency. EPAR summary for the public - Gilenya (fingolimod). European Medicines Agency [online], http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR---Summary-for-the-public/human/002202/WC500104530. pdf (2011).
51. Ingwersen, J. et al. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin. Immunol. http://dx.doi.org/10.1016/j.clim. 2011.05.005.
52. Ross, R. T., Nicolle, L. E. & Cheang, M. The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis. J. Clin. Epidemiol. 50, 63-68 (1997).
53. Rowland, R. & McShane, H. Tuberculosis vaccines in clinical trials. Expert Rev. Vaccines 10, 645-658 (2011).
54. Ristori, G. et al. Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology 53, 1588-1589 (1999).
55. Multiple Sclerosis Therapy Consensus Group. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J. Neurol. 255, 1449-1463 (2008).
56. Fomin, I. et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF-blockers. Ann. Rheum. Dis. 65, 191-194 (2006).
57. FDA. Prescribing information for Gammagard Liquid. US Food and Drug Administration [online], http://www.fda.gov/downloads/BiologicsBloodVaccines/ BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ FractionatedPlasmaProducts/UCM070010.pdf (2011).
58. Briggs, W. A. et al. Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses. Ann. Intern. Med. 92, 471-477 (1980).
59. Koerner, I., Kochs, G., Kalinke, U., Weiss, S. & Staeheli, P. Protective role of beta interferon in host defense against influenza A virus. J. Virol. 81, 2025-2030 (2007).
60. Schwid, S. R., Decker, M. D., Lopez-Bresnahan, M. & Rebif-Influenza Vaccine Study Investigators. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology 65, 1964-1966 (2005).
61. Mehling, M. et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann. Neurol. 69, 408-413 (2011).
62. Mehling, M. et al. Cellular and humoral influenza vaccine-specific immune responses in patients with multiple sclerosis treated with FTY720 or interferon-beta. Neurology 74, A372 (2010).
63. Hauser, S. L. et al. Bcell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
64. Kappos, L. et al. Ocrelizumab in relapsing - remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378, 1779-1787 (2011).
65. Bedognetti, D. et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J. Immunol. 186, 6044-6055 (2011).
66. Yri, O. E. et al. Rituximab blocks protective serological response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 118, 6769-6771 (2011).
67. Gelinck, L. B. et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann. Rheum. Dis. 66, 1402-1403 (2007).
68. van Assen, S. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 62, 75-81 (2010).
69. Oren, S. et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann. Rheum. Dis. 67, 937-941 (2008).
70. Arad, U. et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 29, 1643-1648 (2011).
71. Rehnberg, M. et al. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res. Ther. 12, R111 (2010).
72. Loebermann, M. et al. Immunization in the adult immunocompromised host. Autoimmun. Rev. http://dx.doi.org/10.1016/j.autrev.2011.05.015.
73. Abu-Shakra, M. et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J. Rheumatol. 29, 2555-2557 (2002).
74. Lipnick, R. N. et al. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J. Rheumatol. 12, 1118-1121 (1985).
75. Wagner, D. et al. Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products. Clin. Investig. 72, 350-352 (1994).
76. Wenzl, H., Jahnel, J., Hoegenauer, C., Hinterleitner, T. & Petritsch, W. Inadequately low antibodies against the tick-borne encephalitis virus in immunized patients with inflammatory bowel disease and azathioprine treatment. Gastroenterology 124, 205A (2003).
77. Riminton, D. S., Hartung, H. P. & Reddel, S. W. Managing the risks of immunosuppression. Curr. Opin. Neurol. 24, 217-223 (2011).
78. Department of Health. Immunisation against infectious disease - 'The Green Book' - 2006 updated edition. Department of Health [online], http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-079917 (2006).
79. Centers for Disease Control and Prevention. Recommended adult immunization schedule - United States, 2011. MMWR Morb. Mortal. Wkly Rep. 60, 1-4 (2011).
80. World Health Organization. World immunization schedule. World Health Organization [online], http://www.who.int/entity/immunization-monitoring/data/ schedule-data.xls (2010).
81. Merelli, E. & Casoni, F. Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B. Neurol. Sci. 21, S853-S856 (2000).
82. Myers, L. W. et al. Swine influenza virus vaccination in patients with multiple sclerosis. J. Infect. Dis. 136 (Suppl. 3), S546-S554 (1977).
83. Makela, A., Nuorti, J. P. & Peltola, H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 110, 957-963 (2002).
84. Ahlgren, C., Oden, A., Toren, K. & Andersen, O. Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurol. Scand. 119, 313-320 (2009).
85. Joint Committee on Vaccination and Immunisation. JCVI statement on discontinuation of the routine pneumococcal vaccination programme for adults aged 65 years and older. Department of Health [online], http://www.dh.gov.uk/ prod-consum-dh/groups/dh-digitalassets/@dh/@ab/documents/digitalasset/dh-125122. pdf (2011).
86. Gout, O. & Lyon-Caen, O. Current opinion 2004: The relationship between multiple sclerosis and hepatitis B vaccination in adults [French]. Rev. Neurol. (Paris) 160, 1147-1149 (2004).
87. Hauben, M., Sakaguchi, M., Patadia, V. & Gerrits, C. M. Hepatitis B vaccination and multiple sclerosis: a data mining perspective. Pharmacoepidemiol. Drug Saf. 16, 943-945 (2007).
88. Zuckerman, J. N. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J. Med. Virol. 78, 169-177 (2006).
89. Miller, H., Cendrowski, W. & Shapira, K. Multiple sclerosis and vaccination. Br. Med. J. 2, 210-213 (1967).
90. Fraser, A., Paul, M., Goldberg, E., Acosta, C. J. & Leibovici, L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 25, 7848-7857 (2007).